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Abstract
Disturbances in intestinal microbial ecology and in the immune system of the host have been
implicated as a part of the pathogenesis in chronic fatigue syndrome. Probiotic lactic acid producing
bacteria have been shown to prevent and alleviate gastrointestinal disturbances and to normalize
the cytokine profile which might be of an advantage for patients suffering from chronic fatigue
syndrome. The aim of the study was to evaluate the effect of Lactobacillus paracasei ssp. paracasei
F19, Lactobacillus acidophilus NCFB 1748 and Bifidobacterium lactis Bb12 on fatigue and physical
activity in CFS patients. Fifteen patients fulfilling the criteria set by international researchers in the
field at the US Centre for Disease Control and Prevention in 1994 for chronic fatigue syndrome,
were included in the study. The patients had high fatigue severity scores and high disability scores.
During the first two weeks baseline observations without treatment were assessed, succeeded by
four weeks of intake of a probiotic product and a four-week follow-up period. The fatigue, health
and physical activity was assessed by the use of the Visual Analogue Scales and the SF-12 Health
Survey. Faecal samples were collected and the normal microflora was analysed. Neurocognitive
functions improved during the study period while there were no significant changes in fatigue and
physical activity scores. No major changes occurred in the gastrointestinal microflora. At the end
of the study 6 of 15 patients reported that they had improved according to the assessment
described. The findings in this study that improvement of health is possible to achieve should
encourage further studies with interventions with probiotics in patients with CFS.
Background
Chronic fatigue syndrome (CFS) is a medically unex-
plained illness characterized by persistent and debilitating
fatigue with a minimum duration of six months. The cur-
rent case definition set by an international expert group
1994 includes at least 4 of 8 designated symptoms [1,2].
The prevalence of CFS range between 0.2 and 2.6% in
patients attending primary care and in community based
surveys [3]. In a recent nationwide study from Sweden the
prevalence of CFS-like illness (defined as meeting all self-
reported criteria for CFS but lacking the physical examina-
tion) was 2.4% [4]. The aetiology and pathophysiology of
the syndrome remains unknown but several factors have
been discussed. Among factors that have been implicated
in triggering or mediating the course of the disease are
infective disorders, immune system disorders, neuroen-
docrine abnormalities and neuropsychological impair-
ment [5,6]. It has been suggested that immune
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dysfunctions that has been observed in CFS patients
account for a number of the described symptoms [7]. The
CFS patients have a cytokine imbalance in the peripheral
blood compartment and the system is biased towards a T-
helper (Th) 2 type immunity-oriented pattern. This is
reflected in the high incidence of allergies in CFS patients
[8]. Furthermore, comorbidity between CFS and irritable
bowel syndrome (IBS) has been identified in a number of
studies and a high degree of overlapping symptoms has
been reported [9]. The irritable bowel syndrome is a func-
tional bowel disorder characterized by symptoms of
abdominal pain or discomfort that is associated with dis-
turbed defecation [10]. There is evidence suggesting that
the intestinal microflora of patients with IBS differs from
that of healthy individuals and that the patients have an
abnormal fermentation of food residues [11]. The intesti-
nal microflora in CFS patients have also been shown to be
altered with low levels of Escherichia coli and Bifidobacte-
rium species and with significant increased numbers of
enterococci compared to healthy controls [12]. An ele-
vated number of Candida albicans in the faecal microflora
of CFS patients during the acute phase of illness has
recently been reported [13]. Recently it has also been
pointed out that oxidative stress and food intolerance
might be involved in the pathogenesis of CFS and in the
symptom presentation [14]. It is still uncertain whether
oxidative stress is a cause or a result of the disease. How-
ever, various antioxidants have shown promise as a part of
CFS treatment protocols. The information concerning
food intolerance and CFS is limited but there are indica-
tions of alleviation of symptoms and reduction in fatigue
when food elimination protocols have been followed
[14].
There is increasing evidence that consumption of foods
containing microorganisms is beneficial in prevention
and treatment of gastrointestinal disorders [15]. Several
trials have been performed on the effect of probiotics in
IBS [16-20]. The administration of probiotics resulted in
reduced flatulence and abdominal pain in three of the
studies. However, in one study where enterocoated tablets
were used and in one where a lower concentration of pro-
biotic lactobacilli were administered, no effect was
observed [19,20].
Strains of lactobacilli and bifidobacteria have been inves-
tigated for their antioxidative activity. Several species have
been identified that are capable of chelating metal ions,
scavenging reactive oxygen species and that possess reduc-
ing activity [21]. Human intestinal isolates of lactobacilli
have also been shown to be strong stimulators of inter-
leukin 12 (IL-12) from monocytes [22]. It has been sug-
gested that supplements with lactic acid producing
bacteria apart from modifying the microflora also deviate
the immune phenotype and correct the Th2-type bias that
promotes allergy [23]. Probiotic lactobacilli have further
been shown to be beneficial in the treatment of food
allergy [24]. Lactic acid producing bacteria have recently
been suggested as therapeutic agents in the treatment of
CFS [25]. Potential benefits for CFS patients could be reg-
ulation of the composition of the microflora, the impact
on the cytokine balance and the action of the probiotic
strains as antioxidants. There are no studies performed on
the effects of probiotics in CFS.
The aim of the study was to evaluate the effect of Lactoba-
cillus paracasei ssp. paracasei F19, Lactobacillus acidophilus
NCFB 1748 and Bifidobacterium lactis Bb12 on fatigue and
physical activity in CFS patients.
Methods
Patients
Fifteen patients (10 females and 5 men) fulfilling the
1994 CDC criteria for chronic fatigue syndrome were
included in the study. The patients had both high fatigue
severity scores and high disability scores. The mean age
was 43 years (range 30–56 years, 45 years for women and
39 years for men). None of the patients had used antimi-
crobial agents within the preceding three months. The
patients did not suffer from lactose intolerance or under-
lying chronic inflammatory diseases. The study was
approved by the regional ethical committee in Stockholm
(Ref 2005/888-31/1).
Trial design
The study was designed as an open pilot study with a total
duration of ten weeks per participant. During the first two
weeks baseline observations without treatment were
assessed (to provide baseline mean values of faecal micro-
flora and calprotecin levels) succeeded by four weeks of
treatment and a four-week follow-up period
Administration of supplement
The probiotic product was administered twice daily (2 dl
× 2) during 30 days with start on day 14. The product con-
tained 108 colony forming units (cfu)/ml of the strains
Lactobacillus F19, L. acidophilus NCFB 1748 and B. lactis
Bb12 (Cultura Dofilus Natural Yogurt, Arla Foods, Stock-
holm, Sweden). The fat content was 1.5%.
Fatigue and physical activity
At baseline (day 0), at the end of treatment (day 42) and
at the end of the study (day 70) the patients were assessed
by the Visual Analogue Scales (VAS) [26] to measure the
intensity of symptoms (fatigue, muscle and neurocogni-
tive symptoms as subjectively reported affecting short
term memory and capacity to concentrate). The patients'
self-reported physical activity level and general health sta-
tus were measured with the SF-12 Health Survey once
weekly during the study period [27].Nutrition Journal 2009, 8:4 http://www.nutritionj.com/content/8/1/4
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At the end of the study the patients were asked to evaluate
the treatment by the use of a four-point scale; complete
recovery, improvement, unchanged or impairment of
symptoms.
Sampling procedures – faecel samples
Stool specimens were collected before administration of
the probiotic product (days 0 and 14), on the last day of
administration (day 42) and after the administration (day
70). The faecal samples were collected in sterile plastic jars
and were frozen at -70°C until assayed.
Faecal concentrations of calprotectin
Parts of the collected stool samples were used for determi-
nations of faecal concentrations of calprotectin. Faecal
calprotectin has been shown to closely correlate with
colonic macroscopic and histological inflammation. The
stool samples were prepared and analysed according to
the manufacturers instructions (Calprest Eurospital SpA,
Trieste, Italy). The samples were suspended in buffer,
homogenized and centrifuged followed by ELISA assays of
the supernatants [28].
Microbiological procedures
The stool specimens were suspended in pre-reduced pep-
tone-yeast extract medium, diluted to 10-7 and inoculated
on non-selective and selective media. The aerobic agar
plates were incubated for 24 hours at 37°C and the anaer-
obic plates for 48 hours at 37°C in anaerobic jars
(GasPak; BBL, Cockeysville, MD, USA). After incubation
different colony types were counted, isolated in pure cul-
tures and identified to genus level. All isolates were ana-
lysed according to Gram-reaction and colony
morphology, followed by biochemical tests. API 20E test
kit (Biomeriux SA, Marcy l'Etoile, France) was used for
identification of Enterobacteriaceae. Anaerobic microor-
ganisms were identified by gas-liquid chromatography of
metabolites from glucose. The lower limit of detection
was 102 microorganisms per gram faeces [29].
Compliance
Colony forming units of lactobacilli exhibiting Gram-
stain morphology similar to Lactobacillus F19 were exam-
ined by randomly amplified polymorphic DNA (RAPD-
PCR) to verify the identification. The primer Lbc-19 (5'-
AGTAGCCAC3') was used for screening and OPA-02 (5'-
TGCCGAGCTC-3') for the identification [30]. This was
performed to control for compliance.
Statistical analyses
The quantitative alterations in the normal microflora and
the levels of calprotectin were compared within the group
between pre-treatment (mean of days 0 and 14) and the
end of treatment (day 42) and between pre-treatment and
four weeks after treatment (day 70) and were analysed by
Wilcoxon's signed rank test for paired samples. P values =
0.05 were considered statistically significant and were
adjusted for multiple analyses.
Results
Fatigue
When VAS mean numbers were analysed a significant dif-
ference was found for neurocognitive functions which
improved (p = 0,040) from measurement before treat-
ment (baseline) and at end of follow-up (day 70). No gen-
der-difference was observed. If data were analysed on an
individual level differences were found as shown in Table
1. Both women and men reported both improvement and
worsening of fatigue, muscle-symptoms and of neurocog-
nitive function.
Health and physical activity measured by SF-12
A clear reduction of levels of health were reported at base-
line (day 0) for both measurements (physical and mental)
when compared to the norms for the general Swedish
population (Table 2).
There was no significant change during the treatment
period and during the follow-up.
Table 1: Change of measurements on the visual analogue scale 0–10 (VAS) from baseline (day 0) to follow-up (day 70).
Change of VAS Women, no Men, no
Fatigue Muscle Neurocogn Fatigue Muscle Neurocogn
> 2 1 0 2 0 1 0
0.5–2 5 2 1 1 0 2
01 3 4 2 1 2
-(0.5–2) 1 4 3 1 1 0
< -2 2 1 0 1 2 1
Fatigue = general fatigue, Muscle = muscle symptoms, Neurocogn = neurocognitive symptoms as short-term memory and capacity to concentrateNutrition Journal 2009, 8:4 http://www.nutritionj.com/content/8/1/4
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On an individual basis there were differences as some sub-
jects reported improvement in one or both types of health
while others noticed no change or worsening of health.
Four of 10 women reported improvement in physical
health and 2 in mental health at day 70. One of 5 men
reported improvement in physical health and 1 in mental
health as measured by SF-12 (Table 3).
Subjects report of response
Six of 15 patients reported that they improved when asked
for four given alternatives. (Worsening- one female, no
improvement- five women and three men, improvement-
four women and two men, and complete recovery- none).
Faecal concentrations of calprotectin
The faecal calprotectin levels were normal in all patients
(< 50 mg/kg faeces) although 3 patients had occasionally
higher values (one sample per patient on days 14, 42 and
70 respectively).
Gastrointestinal microflora
No statistically significant alterations in the aerobic intes-
tinal microflora were found while there was increased
numbers of lactobacilli on day 42 and of veillonella on
day 70. The probiotic strain Lactobacillus F19 was recov-
ered from all patients on day 42.
Discussion
Due to the complexity of the cause of CFS it is not reason-
able to believe that a pharmacological compound can be
found that will cure all patients [5]. Also, the high impact
on society points at the necessity to find treatments
through other mechanisms [31]. As the bowel is an
important organ for equilibrium in health [25] the use of
probiotics as "anti-fatigue-food" is a temptating treatment
both from the point of cost and availability as from bio-
logical functions as the neurocognitive system can be
influenced through immune reactions involving
cytokines and anti-oxidants. The theoretical background
is thus solid enough to justify a performance of an inter-
vention. Disturbances reported in the gut flora could not
be reproduced in this study. The design included a period
of baseline observation, treatment and a follow-up
period. The patients became their own controls. The
advantage here is that confounding factors that exist
between individuals affecting the flora as diet and other
daily behaviours are controlled for. However, as CFS has
a fluctuating natural course it could affect the outcome. By
including a satisfying large number of patients this could
be controlled for. The present study is a pilot study.
Another comment that is frequently made is that the pla-
cebo effect should be high in this condition as it is of sub-
jective nature. However, it has been demonstrated that the
placebo effects in CFS is low [32].
The different responses in patients demonstrate the heter-
ogeneity of the patient population. Recent studies have
pointed out the need for subgrouping of patients or
Table 2: SF-12 measurements of physical and mental health at 
baseline (day 0) with norm for the general Swedish population by 
age-group in parenthesis.
Physical health Mental health
Total population 31.0 (51.3) 44.7 (53.0)
Women 30.2 (50.6) 48.2 (52.6)
Men 32.6 (52.9) 37.7 (52.8)
Table 3: Number of women and men reporting change in measurement in SF-12 from baseline (day 0) to end of follow-up (day 70).
Change of measurement in SF-12 Women, No Men, No
Physical Mental Physical Mental
>  1 0 12 01
5–8 0 0 1 0
1–4 3 0 0 0
04 5 3 1
- 1 – 4 10 00
- 5 – 8 00 10
< -10 1 3 0 3Nutrition Journal 2009, 8:4 http://www.nutritionj.com/content/8/1/4
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maybe even a new definition of the syndrome [2,4,33].
When the average is calculated there is no influence of the
intervention but for individuals it can have a clear effect
whether it is improvement or worsening. The low number
of subjects makes it impossible to study gender differ-
ences. There is a significant improvement for the studied
population for neurocognitive functions with sustainabil-
ity as it is demonstrated at the end of the follow-up (day
70). Also almost half of the subjects report improvement
on the four-item scale and a number of subjects report
improvement in general health according to SF-12.
What is very clear is the severity of the condition as
described through SF12 for both physical and mental
health. For both women and men their report of physical
and mental health is less than the norm for the general
Swedish population age 75 years and above. Studies from
the US show that CFS can be as disabling as multiple scle-
rosis, lupus, rheumatoid arthritis, heart disease, end-stage
renal disease, chronic obstructive pulmonary disease and
similar chronic conditions.
The high cost for society has been calculated by the Center
for Disease Control, Atlanta to be more than 9 billion dol-
lars in the US in lost productivity [31], not including med-
ical costs or disability benefits. Our findings confirm that
not only is this a costly condition for society but the
impairment of reported physical and mental health for
the individual is severe and a condition that should be
taken seriously by the medical profession.
Conclusion
The findings in this study that improvement of health is
possible to achieve should encourage further studies with
interventions with probiotics in patients with CFS.
The challenge for the future is to identify the responders
to the therapy with probiotics as this pilot study demon-
strates that some individuals do respond with less fatigue,
less bodily symptoms and better neurocognitive func-
tions.
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